Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

From Furniture to Illumination: Tribesigns Launches Comprehensive Home Lighting…

Tribesigns' newly launched lighting collection features a rich and diverse assortment, including flush mount lights, chandeliers, pendants, lamps, vanity lights, sconces, ceiling fans, and outdoor wall lights. Together, these designs illuminate every corner of the home, casting a warm, gentle glow reminiscent of spring sunlight. Tribesigns' newly launched lighting collection features a rich and diverse assortment, including flush mount lights, chandeliers, pendants, lamps, vanity lights,...

Laboratory Centrifuges Market worth $1.86 billion by 2030 with 2.8% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197749088 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197749088 Browse in-depth TOC on "Laboratory Centrifuges Market" 430 - Tables55 - Figures 350 - Pages By product,the laboratory centrifuges market is segmented into equipment and accessories. In 2025, the equipment segment holds the largest share of the market. Demand for laboratory centrifuge...

Amorepacific Named CES Innovation Award Honoree for Advanced Electronic Skin…

SEOUL, South Korea, Nov. 14, 2025 /PRNewswire/ -- Amorepacific has been named CES 2026 Innovation Award Honoree in the Beauty Tech category for its Skinsight™ technology, marking the company's seventh consecutive year of recognition at the CES Innovation Awards. SEOUL, South Korea , Nov. 14, 2025 /PRNewswire/ -- Amorepacific has been named CES 2026 Innovation Award Honoree in the Beauty Tech category for its Skinsight™ technology, marking the company's seventh consecutive year of...

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S…

INSIDE INFORMATION REGULATED INFORMATIONCorrection and ReplacementNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of GenioFinancings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the...

Leqembi® approved for IV maintenance treatment in the United Kingdom

In the United Kingdom, an estimated 982,000 people are living with dementia,[2] with AD accounting for an estimated 60-70% of cases.[3] These numbers are expected to rise as the population ages. In theUnited Kingdom, an estimated 982,000 people are living with dementia, [2]with AD accounting for an estimated 60-70% of cases. [3] These numbers are expected to rise as the population ages. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody...

Novo Nordisk A/S: Candidate for the Board of Directors will not seek election

Bagsværd, Denmark, 13 November 2025– Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise announced in the notice convening the Extraordinary General Meeting.Earlier today, Mikael Dolsten, who most recently served as the Head of R&D at Pfizer, informed Novo Nordisk that, in spite of his desire to join, he has decided to withdraw his candidacy to the Novo Nordisk...

ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape |…

Download the updated obesity market report featuring key results from ObesityWeek 2025 @ Anti-Obesity Market Download the updated obesity market report featuring key results from ObesityWeek 2025 @ Anti-Obesity Market Let's dive deep into the promising results presented at the ObesityWeek 2025 Novo Nordisk's CagriSema: Dual and Multi-Agonist Dominance The most impactful findings centered on dual agonist therapies.CagriSema,Novo Nordisk'sonce-weekly injection combining...

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S…

INSIDE INFORMATION REGULATED INFORMATIONNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of GenioFinancings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond.Mont-Saint-Guibert, Belgium – November 13, 2025, 2025, 10:11pm CET / 4:11 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the...

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated…

Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external collaborationsNewin vivopre-clinical data evaluating the Nanoprimer in combination with therapeutic vaccines were presented at the 2025Partnership Opportunities in Drug Deliveryconference (PODD) that will serve as the foundation for an initial internal proprietary...

Nyxoah Reports Third Quarter 2025 Financial and Operating Results

REGULATED INFORMATIONNyxoah Reports Third Quarter 2025 Financial and Operating ResultsUS launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through...

Bavarian Nordic Announces Changes to the Board of Directors

COPENHAGEN, Denmark, November 13, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that Chair of the Board, Luc Debruyne has decided to step down from the board with immediate effect. The Board has appointed Vice Chair Anne Louise Eberhard as new Chair of the Board.“After careful reflection on both the process and the outcome of the recent takeover attempt, I have decided to step down to enable the board of Bavarian Nordic to focus on the company’s next phase of development...

Bone Health Supplements Market to Reach $23.1 billion, Globally, by 2034 at 5.3%…

Request Sample of the Report on Bone Health Supplements Market Forecast 2034 -https://www.alliedmarketresearch.com/request-sample/A294439 Request Sample of the Report on Bone Health Supplements Market Forecast 2034 -https://www.alliedmarketresearch.com/request-sample/A294439 Market Introduction The bone health supplements market encompasses a wide range of nutraceuticals, minerals, and specialized formulations designed to support skeletal strength, maintain bone density, and...

Sanofi: Information concerning the total number of voting rights and shares –…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l’Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of €2,454,937,946 Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...

BASTIDE : Organic growth of 8.3% in first-quarter 2025-2026: Sustained growth in…

Caissargues, November 13, 2025 – Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2025-2026, ending September 30, 2025. In € millions 2024-2025 published 2024-2025 restated (IFRS 5)* 2025-2026 published Change First-quarter revenue 133.8 116.9 126.3 +8…

Ramsay Sante : Interim results at the end of September 2025

PRESS RELEASE Paris, 13 thNovember 2025 Interim results at the end of September 2025Revenue growth of 2.6% and Group EBITDA up 6.5% despitereduction in public funding; resilient operating performanceActivity growth and cost control compensate constrained funding Unaudited group revenue for the quarter ending 30 September 2025 increased by 2.6% to 1.21bn€ supported by activity volume growth, price indexation in Sweden and favourable foreign exchange...

Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Daix (France), New York City (New York, United States), November 13, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (" MASH "), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET). Trading of the…

Medical Radiation Shielding Market is expected to generate a revenue of USD 3.27…

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/medical-radiation-shielding-market-3657/request-sample The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/medical-radiation-shielding-market-3657/request-sample Free Sample Includes: Why Radiation Shielding Is Now a Boardroom-Level Priority Core...

Next Generation Sequencing (NGS) Market Poised to Hit $42.25 Billion by 2033…

Download a free sample copy of this report : Next Generation Sequencing Market Download a free sample copy of this report :Next Generation Sequencing Market The next-generation sequencing (NGS) market is propelled by a confluence of factors, starting with a high degree of technological innovation, which includes ongoing advances in single-cell, long-read sequencing, and AI-driven data analysis, exemplified by product launches like Roche's SBX sequencing technology with Xpandomer...

Alpha Dextrin Market to Reach $102,156.7 thousand, Globally, by 2034 at 3.8%…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A325769 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A325769 Prime determinants of growth The alpha dextrin market is driven by factors such as increase in demand for excipients, and product stabilization and texture enhancement. However, high production costs and availability of cheaper alternatives restrict the market growth...

Inventiva announces pricing of upsized public offering of approximately $150M of…

Daix (France), New York City (New York, United States), November 13, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (" MASH "), today announced the pricing of its previously announced underwritten public offering, in the United States only, of 38,961,038 new American…

Bioxodes presents BIOX-101 clinical data showing breakthrough potential for…

Voting Rights and Shares Capital of the Company

Bavarian Nordic Announces Interim Results for the First Nine Months of 2025

German Women's Wellness Brand Princess Luna Presents at CIIE, Showcasing…

From Furniture to Illumination: Tribesigns Launches Comprehensive Home Lighting…

Laboratory Centrifuges Market worth $1.86 billion by 2030 with 2.8% CAGR |…

Amorepacific Named CES Innovation Award Honoree for Advanced Electronic Skin…

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S…

Leqembi® approved for IV maintenance treatment in the United Kingdom

Novo Nordisk A/S: Candidate for the Board of Directors will not seek election

ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape |…

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S…

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated…

Nyxoah Reports Third Quarter 2025 Financial and Operating Results

Bavarian Nordic Announces Changes to the Board of Directors

Bone Health Supplements Market to Reach $23.1 billion, Globally, by 2034 at 5.3%…

Sanofi: Information concerning the total number of voting rights and shares –…

BASTIDE : Organic growth of 8.3% in first-quarter 2025-2026: Sustained growth in…

Ramsay Sante : Interim results at the end of September 2025

Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Medical Radiation Shielding Market is expected to generate a revenue of USD 3.27…

Next Generation Sequencing (NGS) Market Poised to Hit $42.25 Billion by 2033…

Alpha Dextrin Market to Reach $102,156.7 thousand, Globally, by 2034 at 3.8%…

Inventiva announces pricing of upsized public offering of approximately $150M of…